Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S. commercial ...
Prognostic and predictive impact of Ki-67 before and after neoadjuvant chemotherapy on PCR and survival: Results of the GeparTrio trial. NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and ...
Results of pooled analyses from two phase III trials of 1,085 patients (pts) with advanced melanoma: Oblimersen (OBL) plus dacarbazine (DTIC) versus DTIC alone. Background: The RAF/MEK/ERK pathway is ...
A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumours Unit of the Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research ...
Newswise - ORLANDO, Fla. - The combination of two compounds that inhibit two of the most frequently mutated cancer pathways is showing promise in an ongoing Phase I trial, according to data presented ...
PAS-004 is being tested in a phase 1 trial for MAPK pathway-driven advanced solid tumors, with dosing initiated at 30 mg. The trial is multicenter, open-label, and dose-escalation, assessing safety, ...
It is known that an abnormal activation of the mitogen-activated protein kinase (MAPK) pathway is involved in tumor formation and progression, where MEK1 and MEK2 are the key proteins involved in this ...
Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor mirdametinib, a large multicenter study of the rare condition showed. Overall, 53 ...
At the International Symposium on Pediatric Neuro-Oncology (ISPNO), researchers presented findings from two trials aimed at overcoming resistance to standard BRAF/MEK-targeted therapies in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results